Dr. Berger’s session will explore the development of MSK-IMPACT and MSK-ACCESS, MSK’s comprehensive genomic profiling and cfDNA analysis programs. These initiatives address the need for large-scale molecular profiling across diverse tumor types. A key focus will be the role of matched tumor-normal sequencing in reducing biological false positives, ensuring true somatic variants are accurately identified while enabling seamless integration of germline analysis. Dr. Berger will also discuss how SOPHiA GENETICS has become a key collaborator, empowering MSK to expand the accessibility of precision oncology globally through scalable, cloud-based solutions.

Learning Objectives

1. Understand the evolution and unique features of MSK’s genomic profiling programs (MSK-IMPACT and MSK-ACCESS) and their role in advancing precision oncology.
2. Explore the critical benefits of matched tumor-normal sequencing in reducing biological false positives, enabling accurate somatic variant identification, and enhancing germline analysis.
3. Analyze real clinical cases demonstrating how MSK’s genomic technologies inform decision-making.